Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.47Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 12.48%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Ionis demonstrated strong financial performance and successful product launches despite external market uncertainties. The company increased its financial guidance and highlighted significant growth potential through upcoming product launches. However, challenges remain in patient identification and potential market disruptions.Company Guidance
During the call, Ionis provided updated financial guidance, significantly raising their 2025 projections. Revenue guidance was increased by over 20% due to strong first-quarter results and successful licensing transactions, now expected to be in the range of $725 million to $750 million. The company also improved its non-GAAP operating loss guidance by nearly 25%, projecting it to be less than $375 million, and anticipates ending the year with $1.9 billion in cash. The revenue increase was attributed to the early commercial success of TRYNGOLZA, which generated over $6 million in net product sales in its first full quarter, and the completion of strategic licensing deals. Ionis emphasized its confidence in achieving substantial and sustained revenue growth, supported by a robust pipeline with potential multibillion-dollar peak sales.Increased Financial Guidance for 2025
Ionis increased its 2025 revenue guidance by more than 20% due to strong first-quarter results and recent successful licensing transactions, projecting $725 million to $750 million in revenue.
Successful Launch of TRYNGOLZA
TRYNGOLZA, the first FDA-approved treatment for familial chylomicronemia syndrome, exceeded expectations with over $6 million in net product sales in its first full quarter on the market.
Upcoming Launches and Product Pipeline
Ionis is preparing for the launch of donidalorsen for hereditary angioedema in the third quarter and expects data from two Phase III programs later this year, which could lead to significant market opportunities.
Strong Commercial Revenue Growth
Commercial product revenues grew 28% year-over-year, with robust contributions from TRYNGOLZA, SPINRAZA, and WAINUA.
---
IONS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IONS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $29.81 | $30.71 | +3.02% |
Feb 19, 2025 | $31.95 | $31.81 | -0.44% |
Nov 06, 2024 | $38.80 | $39.04 | +0.62% |
Aug 01, 2024 | $49.46 | $51.32 | +3.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ionis Pharmaceuticals (IONS) report earnings?
Ionis Pharmaceuticals (IONS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Ionis Pharmaceuticals (IONS) earnings time?
Ionis Pharmaceuticals (IONS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IONS EPS forecast?
IONS EPS forecast for the fiscal quarter 2025 (Q2) is -0.47.
---